Stryker Rejuvenate and ABG II Cases Growing
The Stryker Hip Litigation Attorneys at Babbitt & Johnson P.A. consider sharp litigation increases and question FDA medical device approval process.
WEST PALM BEACH, FL. May 2014 – The United States Judicial Panel on Multidistrict Litigation (JPML) statistics show sharp increases in pending cases against Stryker Rejuvenate and ABG II hip implants in only a few months. In February 2014, there were 576 pending cases. That number jumped to 699 in April 2014. These increases can be attributed to more patients coming forward to seek legal advice because they are experiencing the effects of these hip implants and want to find out what their options are. (MDL Case No. 2441, Stryker Rejuvenate and ABG II Hip Implant Products Liability Litigation Donovan W Frank (U.S. District Judge))
As experienced Stryker Hip Litigation attorneys, Babbitt & Johnson, P.A. has been following the complexities of the Stryker case closely.
Experienced in handling large medical device cases such as this one, the attorneys at Babbitt & Johnson P.A. believe the case increase is due to the fact that firms like theirs have encouraged people injured as a result of hip replacement surgery, to speak to knowledgeable Stryker Rejuvenate and ABG II Lawyers about their rights and what they can do to put their life back together.
The attorneys at Babbitt & Johnson, P.A. also take the long view of this medical device case, and suggests that the FDA approval process bears some responsibility for the product reaching the market.
The Stryker Corporation is one of the world’s largest medical device companies. In 2010, it released its Rejuvenate and ABG II devices; a modular hip system of femoral bodies and necks. Heavily promoted to surgeons, the product was touted for its enhanced stability, proven modularity, and inoperative flexibility. Yet the Stryker Rejuvenate and ABG II hip implants were not obligated to undergo more rigorous and stringent clinical trials as other high-risk or Class II medical devices would. Instead, this product obtained FDA approval through the less stringent 510(k) process that allows a medical device manufacturer to obtain FDA approval without clinical trials as long as the product is “substantially equivalent” to a product already on the market. (MDL Case No. 2441, Stryker Rejuvenate and ABG II Hip Implant Products Liability Litigation Donovan W Frank (U.S. District Judge))
Babbitt & Johnson, P.A. believes that high-risk, Class II medical device manufacturers, like Stryker should be required to conduct more testing and complete the clinical trials before submitting their application for FDA approval so that these high-risk products will be much safer for patients in the future.
If you have been injured from a Stryker hip implant device, contact our Stryker Rejuvenate and ABG II attorneys for a free confidential consultation and case evaluation at www.babbitt-johnson.com or (561) 375-2841.
About Babbitt & Johnson P.A.
Since 1967, the law firm of Babbitt & Johnson P.A., in West Palm Beach, Florida has been seeking justice for its clients against people and businesses whose negligent behavior has caused serious injury. To find out more about how Babbitt & Johnson P.A. can help, visitwww.babbitt-johnson.com or call (561) 375-2841.
Sources:
Stryker Rejuvenate and ABG II Hip Implant Products Liability Litigation Donovan W Frank (U.S. District Judge) MDL Case No. 2441